Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
Unknown status
Oslo University Hospital
Phase 4
2011-08-01
The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and
bleomycin and fibrovein in the treatment of venous malformation.
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Completed
American Rhinologic Society
Phase 1/Phase 2
2011-02-01
The purpose of this study is to test a novel and tolerable office-based treatment method,
sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to
Hereditary Hemorrhagic Telangiectasia (HHT) disease.
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Completed
University of Minnesota
Phase 1/Phase 2
2011-02-01
The purpose of this study is to test a novel and tolerable office-based treatment method,
sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to
Hereditary Hemorrhagic Telangiectasia (HHT) disease.
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Completed
University of Minnesota - Clinical and Translational Science Institute
Phase 1/Phase 2
2011-02-01
The purpose of this study is to test a novel and tolerable office-based treatment method,
sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to
Hereditary Hemorrhagic Telangiectasia (HHT) disease.
A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency
Recruiting
Vascular Insights, LLC
Phase 2
2017-09-22
VICARES is a prospective randomized, controlled, multi-center, double blind study treating
venous insufficiency associated with incompetent saphenous veins with 1% and 3% Sodium
Tetradecyl Sulfate (STS) solution utilizing the ClariVein system.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
